0001140361-23-054516.txt : 20231122 0001140361-23-054516.hdr.sgml : 20231122 20231122193430 ACCESSION NUMBER: 0001140361-23-054516 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231120 FILED AS OF DATE: 20231122 DATE AS OF CHANGE: 20231122 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chen Ruoyu CENTRAL INDEX KEY: 0001982080 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51173 FILM NUMBER: 231434796 MAIL ADDRESS: STREET 1: 12730 HIGH BLUFF DRIVE STREET 2: SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GYRE THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001124105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 562020050 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (619) 949-3681 MAIL ADDRESS: STREET 1: 12770 HIGH BLUFF DRIVE, SUITE 150 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST BIOSCIENCES, INC. DATE OF NAME CHANGE: 20150820 FORMER COMPANY: FORMER CONFORMED NAME: TARGACEPT INC DATE OF NAME CHANGE: 20000919 4 1 form4.xml X0508 4 2023-11-20 0001124105 GYRE THERAPEUTICS, INC. GYRE 0001982080 Chen Ruoyu C/O GYRE THERAPEUTICS, INC. 12770 HIGH BLUFF DRIVE, SUITE 150 SAN DIEGO CA 92130 true Chief Financial Officer false Stock Option (Right to Buy) 0.75 2023-11-20 4 A 0 578540 0 A 2030-10-31 Common Stock 578540 578540 D Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent"), terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan. These options are vested in full. /s/ Ruoyu Chen 2023-11-22